Business
Vertex Reports Fourth Quarter and Full Year 2025 Financial Results
BOSTON, February 12, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2025, and provided its full year 2026 financial guidance.
About this update from Vertex Pharmaceuticals Incorporated
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":252,"url":"https://media.zenfs.com/en/business-wire.com/4f55035b309575ae7f9ad4c1f4d44a56"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pdWJ5H7qk0jMxiaLDPPL6A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/4f55035b309575ae7f9ad4c1f4d44a56","width":480,"height":252}},"lazy":false},{"type":"text","content":"— Full year total revenue of $12.0 billion, a 9% increase compared to full year 2024; fourth quarter total revenue of $3.19 billion, a 10% increase compared to fourth quarter 2024 —","length":181,"tagName":"p","attribs":{}},{"type":"text","content":"— Company provides full year 2026 total revenue guidance of $12.95 billion to $13.1 billion, with non-CF products expected to contribute $500 million or more in revenue —","length":170,"tagName":"p","attribs":{}},{"type":"text","content":"— Broad mid- and late-stage clinical pipeline accelerates with multiple proof-of-concept and pivotal programs advancing; on track to complete BLA filing for U.S. accelerated approval of povetacicept in IgAN in the first half of 2026 —","length":234,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, February 12, 2026--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2025, and provided its full year 2026 financial guidance.","length":254,"tagName":"p"},{"type":"text","content":""2025 marked a year of strong revenue growth, commercial diversification, and pipeline advancement," said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. "Our focus in 2026 remains on executing across the CF franchise, bringing CASGEVY to more patients around the globe and continuing to launch JOURNAVX, as we also prepare for the anticipated near‑term commercialization of povetacicept in IgAN. With expanding leadership in CF, exciting commercial momentum, and multiple mid- and late-stage programs advancing, Vertex is well positioned to deliver long‑term value for patients and shareholders."","length":644,"tagName":"p"},{"type":"text","content":"Fourth Quarter 2025 Results","length":27,"tagName":"p"},{"type...